Seattle Genetics Stock Price - SGEN

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
After Hours
Last Trade
Last $ 119.90 ◊ 0.00 (0.00%)
Company Name Stock Ticker Symbol Market Type
Seattle Genetics Inc SGEN NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.94 -0.78% 119.90 120.9163 118.102 120.37 120.84 19:59:41
Bid Price Ask Price Spread Spread % News
115.50 130.00 14.50 11.15% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
13,799 1,237,551 $ 119.44 $ 147,813,512 1,115,631 51.50 - 122.26
Last Trade Time Type Quantity Stock Price Currency
17:56:01 formt 38,503 $ 119.90 USD

Seattle Genetics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 20.55B 171.39M $ -222.69M -1.43 -82.66 168.82M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 30.00 1.50%

more financials information »

Seattle Genetics News

Loading Messages....

Latest SGEN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SGEN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week112.20122.26111.575116.781,349,4737.706.86%
1 Month100.69122.2699.27110.151,015,77919.2119.08%
3 Months73.54122.2665.4492.261,016,36246.3663.04%
6 Months64.76122.2663.0282.12966,76155.1485.15%
1 Year56.88122.2651.5075.83925,16863.02110.79%
3 Years71.10122.2645.3164.82959,13748.8068.64%
5 Years37.13122.2626.0254.82974,07182.77222.92%

Seattle Genetics Description

Seattle Genetics is a biotech firm focused on developing antibody-drug conjugates. The company's lead product, Adcetris, has received approval for advanced front-line, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. The company has several other oncology programs in pivotal trials, including enfortumab vedotin for bladder cancer. Seattle Genetics also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.

Your Recent History
Seattle Ge..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.